

August 01, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 540737

Dear Sir/Ma'am,

Sub: Outcome of Board Meeting held on August 01, 2025

With reference to the captioned subject matter, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. August 01, 2025 has inter alia considered and approved Unaudited (Standalone & Consolidated) Financial Results for the first Quarter ended on 30th June, 2025. The Financial Results along with Limited Review Report are enclosed herewith.

The Meeting of the Board of Directors of the Company commenced at 04:00 p.m. and concluded at 04:55 p.m.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

Shree Ganesh Remedies Limited

ADITYA
VIKRAMBHAI
PATEL

Digitally signed by
ADITYA
VIKRAMBHAI PATEL

Aditya Patel
Company Secretary and Compliance Officer

Enclosed: - As stated above

Independent Auditor's Review Report on Unaudited Quarterly Standalone Financial Results of Shree Ganesh Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors,
Shree Ganesh Remedies Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Shree Ganesh Remedies Limited** ("the Company") for the quarter ended June 30th, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Mail : office@cachaudharyshah.com
Website : www.cachaudharyshah.com
Phone : +91 79 - 4890 4596
Mobile : +91 93774 71779
 : +91 94616 36460
 : +91 97692 99002

Head Office : 406, Central Business Space, Opp. Sukhsagar Complex, Usmanpura, Ahmedabad, Gujarat - 380 013.
Branch Office : B-102, Panchratna Chs, Opp. Dainik Chinese Corner, Thane West, Mumbai, Maharashtra, - 400 601.
Other Branches : Bengaluru (Karnataka) | Kolhapur (Maharashtra) | Jaipur (Rajasthan) | London (United Kingdom)



CHAUDHARY SHAH & ASSOCIATES LLP

LLPN : AAZ-5550

CHARTERED ACCOUNTANTS

Ahmedabad | Mumbai | Bengaluru | Kolhapur | Jaipur | London (UK)

Other Matter

5. The comparative financial information of the Company for the quarter ended June 30th, 2024 & year to date period from April 1, 2024 to June 30, 2024 included in the Statement, have been reviewed/ audited by the predecessor auditor. The report of the predecessor auditor on the comparative financial information expressed an unmodified conclusion/opinion.

Our opinion is not modified in respect of this matter.

For, Chaudhary Shah & Associates LLP
Chartered Accountants
FRN: 006212C/W100789


01-08-2025



Shubham Jain
Designated Partner
M.No. 474949
UDIN: 25474949BMJHWE4746

Place: Ahmedabad
Date: 01.08.2025

INDIA

Mail : office@cachaudharyshah.com
Website : www.cachaudharyshah.com
Phone : +91 79 - 4890 4596
Mobile : +91 93774 71779
 : +91 94616 36460
 : +91 97692 99002

Head Office : 406, Central Business Space, Opp. Sukhsagar Complex, Usmanpura, Ahmedabad, Gujarat - 380 013.
Branch Office : B-102, Panchratna Chs, Opp. Dainik Chinese Corner, Thane West, Mumbai, Maharashtra, - 400 601.
Other Branches : Bengaluru (Karnataka) | Kolhapur (Maharashtra) | Jaipur (Rajasthan) | London (United Kingdom)

Independent Auditor's Review Report on Unaudited Quarterly Consolidated Financial Results of Shree Ganesh Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors,
Shree Ganesh Remedies Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Shree Ganesh Remedies Limited ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entity:

Name of the Entity	Relationship
SGRL USA INC	Wholly Owned Subsidiary [with effect from January 8, 2024]

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required

to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other matters

6. The accompanying Statement includes the unaudited interim financial results/financial information of 1 (one) subsidiary located outside India, whose unaudited interim financial results/financial information reflect total revenue of ₹ NIL lakhs, total net profit/ (loss) after tax (including due to exchange translation) of ₹ (0.43) lakhs and total comprehensive income/(loss) (including due to exchange translation) of ₹ (0.45) lakhs, for the quarter ended June 30th, 2025 as considered in the Statement. The management of the Holding Company has prepared and certified the unaudited interim financial results/ financial information of this 1 (one) subsidiary in accordance with Ind AS and accounting principles generally accepted in India, and our opinion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary, is based solely on such financial results/ financial information. In our opinion and according to the information and explanation given to us by the management of the Holding Company, this unaudited interim financial results/ financial information is not material to the Group.
7. The accompanying Statement, the comparative Consolidated financial information of the Company for the quarter ended June 30th, 2024 & year to date period from April 1, 2024 to June 30, 2024 included in the Statement, have been reviewed by the predecessor auditor. The report of the predecessor auditor on the comparative Consolidated financial information for the aforesaid Period expressed an unmodified conclusion/opinion.

Our conclusion on the Statement is not modified in respect of the above matters.

For, Chaudhary Shah & Associates LLP
Chartered Accountants
FRN: 006212C/W100789



01-08-2025



Shubham Jain
Designated Partner
M.No. 474949
UDIN: 25474949BMJHWF2304

Place: Ahmedabad
Date: 01.08.2025

Mail : office@cachaugharyshah.com
Website : www.cachaugharyshah.com
Phone : +91 79 - 4890 4596
Mobile : +91 93774 71779
: +91 94616 36460
: +91 97692 99002

Head Office : 406, Central Business Space, Opp. Sukhsagar Complex, Usmanpura, Ahmedabad, Gujarat - 380 013.
Branch Office : B-102, Panchratna Chs, Opp. Dainik Chinese Corner, Thane West, Mumbai, Maharashtra, - 400 601.
Other Branches : Bengaluru (Karnataka) | Kolhapur (Maharashtra) | Jaipur (Rajasthan) | London (United Kingdom)

Consolidated Financial Results For the Quarter ended June 30, 2025

Sr. No.	Particular	Quarter ended			Year ended
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	INCOME				
I	Revenue from Operations	2,466.79	2,443.19	2,477.99	10,859.65
II	Other Income	66.17	228.65	54.47	372.95
III	Total Income (I +II)	2,532.96	2,671.84	2,532.46	11,232.60
	EXPENSES				
IV	Cost of Materials Consumed	874.05	951.41	883.90	3,738.11
	Purchases of Stock-in-trade	-	-	-	1.23
	Changes in inventories of Finished Goods, Stock-in-trade and Work-in-progress	-1.27	(367.02)	(44.85)	(151.99)
	Employee Benefit Expenses	269.83	268.89	235.17	1,011.89
	Finance Costs	94.01	96.54	31.86	210.69
	Depreciation and Amortisation expense	242.01	242.45	201.83	956.69
	Other Expenses	594.52	602.16	591.37	2,339.21
	Total Expenses (IV)	2,073.16	1,794.42	1,899.28	8,105.84
V	Profit/(Loss) before Tax (III-IV)	459.80	877.42	633.18	3,126.76
VI	Tax Expense				
	Current Tax	102.31	226.47	165.55	804.68
	Deferred Tax	12.99	(8.05)	2.75	(4.46)
	(Excess)/Short provision of tax of earlier years	-	-	-	19.70
	Total Tax Expense (VI)	115.29	218.42	168.30	819.92
VII	Profit/(Loss) for the period after Tax (V-VI)	344.51	659.00	464.88	2,306.84
VIII	OTHER COMPREHENSIVE INCOME				
	Items that will not be reclassified to profit or loss				
	Exchange Differences in translating the financial statements of foreign operations	(0.02)	0.01	-	0.17
	Remeasurement Gain/ (Loss) on Defined Measurement Benefit Plans	(0.44)	1.50	1.00	(1.75)
	Income Tax Relating to above	0.11	(0.38)	(0.26)	0.44
	Total Other Comprehensive Income for the period (VIII)	(0.35)	1.13	0.74	(1.15)
IX	Total Comprehensive Income for the period (VII+VIII)	344.16	660.13	465.62	2,305.70
X	Earning Per Share of ₹ 10 Par Value				
	Paid - up Equity Share Capital (Face Value ₹ 10 each)	1,283.76	1,283.76	1,283.76	1,283.76
	Basic (In ₹ per share)	2.68	5.13	3.62	17.96
	Diluted (In ₹ per share)	2.68	5.13	3.62	17.96

For Shree Ganesh Remedies Ltd.


Chandulal Manubhai Kothia
DIN: 00652806
Managing Director

Place: Ankleshwar
Date: 01-08-2025



For Chaudhary Shah and Associates LLP
Chartered Accountants, FRN:006212C/W100789


Shubham Jain
Designated Partner
M.No. 474949
Place: Ahmedabad
Date: 01-08-2025



Head Office :
Plot No. 6011, 6012, 6002 & 6003,
GIDC Estate, Ankleshwar - 393 002,
Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No. : L24230GJ1995PLC025661

(Unit-2) :
Plot No. 6714/2,-6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1ZQ (Zero)



www.ganeshremedies.com
WEBSITE
contact@ganeshremedies.com
E MAIL

Standalone Financial Results For the Quarter Ended June 30, 2025

Sr. No.	Particular	Quarter ended			₹ In Lakhs
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	INCOME				
I	Revenue from Operations	2,466.79	2,443.19	2,477.99	10,859.65
II	Other Income	66.17	228.66	54.47	372.95
III	Total Income (I + II)	2,532.96	2,671.85	2,532.46	11,232.60
	EXPENSES				
IV	Cost of Materials Consumed	874.05	951.40	883.90	3,738.11
	Purchases of Stock-in-trade	-	-	-	1.23
	Changes in inventories of Finished Goods, Stock-in-trade and Work-in-progress	-1.27	(367.03)	(44.85)	(151.99)
	Employee Benefit Expenses	269.83	268.88	235.17	1,011.89
	Finance Costs	94.01	95.85	31.55	207.73
	Depreciation and Amortisation expense	242.01	242.45	201.83	956.69
	Other Expenses	594.52	602.17	591.37	2,339.21
	Total Expenses (IV)	2,073.16	1,793.73	1,898.97	8,102.87
V	Profit/(Loss) before Tax (III-IV)	459.80	878.12	633.49	3,129.73
VI	Tax Expense				
	Current Tax	101.87	226.47	165.55	804.68
	Deferred Tax	12.99	(8.05)	2.75	(4.46)
	(Excess)/Short provision of tax of earlier years	-	0.00	-	19.70
	Total Tax Expense (VI)	114.86	218.42	168.30	819.92
VII	Profit/(Loss) for the period after Tax (V-VI)	344.94	659.70	465.19	2,309.81
VIII	OTHER COMPREHENSIVE INCOME				
	Items that will not be reclassified to profit or loss				
	Exchange Differences in translating the financial statements of foreign operations	-	-	-	-
	Remeasurement Gain/ (Loss) on Defined Measurement Benefit Plans	(0.44)	1.50	1.00	(1.75)
	Income Tax Relating to above	0.11	(0.38)	(0.26)	0.44
	Total Other Comprehensive Income for the period (VIII)	(0.33)	1.12	0.74	(1.31)
IX	Total Comprehensive Income for the period (VII+VIII)	344.62	660.82	465.93	2,308.50
X	Earning Per Share of ₹ 10 Par Value				
	Paid - up Equity Share Capital (Face Value ₹ 10 each)	1,283.76	1,283.76	1,283.76	1,283.76
	Basic (In ₹ per share)	2.69	5.13	3.62	17.98
	Diluted (In ₹ per share)	2.69	5.13	3.62	17.98

For Shree Ganesh Remedies Ltd.

Chandul

Chandul Manubhai Kothia
DIN: 00652806
Managing Director

Place: Ankleshwar
Date: 01-08-2025



For Chaudhary Shah and Associates LLP

Chartered Accountants, FRN:006212C/W100789

Shubham
01-08-2025

Shubham Jain
Designated Partner
M.No. 474949
Place: Ahmedabad
Date: 01-08-2025



Head Office :
Plot No. 6011, 6012, 6002 & 6003,
GIDC Estate, Ankleshwar - 393 002,
Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No.: L24230GJ1995PLC025661

(Unit-2) :
Plot No. 6714/2, -6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1ZQ (Zero)



www.ganeshremedies.com
WEBSITE
contact@ganeshremedies.com
E MAIL

Notes to Financial Results for the Quarter ended June 30, 2025

- 1 The above results which are published have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 01, 2025. The Financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The Company is primarily engaged in the business of Bulk Drug Intermediates, which constitute a single reportable segment in accordance with Ind AS 108 - "Segment Reporting".
- 3 Earnings per share (EPS) is calculated on the weighted average of share capital outstanding during the year as per Ind AS 33 on "Earnings Per Share". EPS for the Quarter ended June 30, 2025, March 31, 2025, June 30, 2024 are not annualised.
- 4 Kamalam Foundation which is incorporated under Section 8 of the Companies Act, 2013 is prohibited to give any right over their profits to its members and accordingly, no share in surplus of Kamalam Foundation is considered to be that of the Company for the purpose of preparation and presentation of consolidated financial results/financial statements/financial information.
- 5 Previous year's / period's figures are regrouped wherever necessary to make them comparable with current year's / period's grouping

For Shree Ganesh Remedies Ltd.

Chandulal Manubhai Kothia
DIN: 00652806
Managing Director



Place: Ankleshwar
Date: 01-08-2025

For Chaudhary Shah and Associates LLP

Chartered Accountants, FRN:006212C/W100789

Shubham Jain
Designated Partner
M.No. 474949
Place: Ahmedabad
Date: 01-08-2025



Head Office :
Plot No. 6011, 6012, 6002 & 6003,
GIDC Estate, Ankleshwar - 393 002,
Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No. : L24230GJ1995PLC025661

(Unit-2) :
Plot No. 6714/2, -6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1ZQ (Zero)



www.ganeshremedies.com
WEBSITE
contact@ganeshremedies.com
EMAIL